|Allovir Inc., of Cambridge, Mass.||ALVR-109||Allogeneic virus-specific T-cell therapy||COVID-19 infection||FDA cleared IND application for proof-of-concept trial, expected to begin in fourth quarter of 2020|
|Celltrion Group, of Incheon, South Korea||CT-P59||COVID-19 Spike glycoprotein inhibitor||COVID-19 infection||Korea's MFDS cleared IND application for pivotal phase II/III trial in people with mild to moderate symptoms of infection; top-line data from phase II portion expected by year-end 2020|
|Chemocentryx Inc., of Mountain View, Calif.||Avacopan||Complement 5a receptor inhibitor||Vasculitis||FDA accepted NDA covering treatment of ANCA-associated disease, setting July 7, 2021, PDUFA date; agency did not issue determination on advisory committee meeting|
|Hutchison China Meditech Ltd. (Chi-Med), of Hong Kong||Surufatinib||Angio-immuno kinase inhibitor||Pancreatic neuroendocrine tumors||China's NMPA accepted NDA covering treatment of advanced disease|
|Roche Holding AG, of Basel, Switzerland||Risdiplam||SMN2 gene modulator||Spinal muscular atrophy||U.K.’s MHRA issued positive opinion on early access to medicines scientific opinion for patients, 2 months and older with type 1 or type 2 SMA not suitable for authorized treatments|
|Sorrento Therapeutics Inc., of San Diego||STI-1499 (COVI-GUARD)||COVID-19 Spike glycoprotein inhibitor||COVID-19 infection||FDA cleared IND for phase I trial in people hospitalized with infection|
|Zynerba Pharmaceuticals Inc., of Devon, Pa.||Zygel||Cannabidiol gel||22q11.2 deletion syndrome||FDA granted orphan designation|
For more information about individual companies and/or products, see Cortellis.